Emyria Limited | Data-backed drug development and clinical care

We Are

A clinical biotech creating tomorrow’s therapies from today’s patient stories.

News & Events

Get up to speed with our latest news.

Drug Development

ULTRA - PURE CANNABINOIDS

Powered By Real World Evidence

Novel Formulation	Medical Indication	Dose Optimisation	Safety Trials	Pivotal Trials	Approval
EMD-RX5 Over the Counter	Psychological Distress
EMD-RX5 Over the Counter	Irritable Bowel Syndrome
EMD-RX7 Prescription	Multiple Medical Conditions
EMD-RX9 Prescription	Multiple Medical Conditions

New Drug Discovery

MDMA - LIKE MEDICINE PROGRAMS

Ongoing Library Expansion

Program	Medical Indication	Discovery	Pre-Clinical	Phase 1	Pivotal Trials	Approval
Program 01 HIGHER POTENCY MDMA	e.g. Drug-assisted psychotherapy
Program 02 SELECTED BRAIN TARGETS	e.g. Parkinson's
Program 03 SELECTED NON-BRAIN TARGETS	e.g. Fibrotic Disease

Innovation

Technology	Description	Concept	Design	Submission	Approval	Launch
OPENLY REMOTE HEALTH TRACKER	Vital Signs Tracked Via Smartphone Camera	CLASS 2A MEDICAL DEVICE

For Investors

Ours is a collaborative vision and venture. We’re bringing people and partners together for the greater good: patients, clinicians, researchers, medical innovators and, of course, investors.

0

%

FDA approvals where real-world evidence (RWE) was provided, and growing.

0

+

Unique data points collected per patient.

$

0

T USD

Trillion USD cost of chronic disease and mental health per year in the US.